Krystal Biotech, Inc.
http://www.krystalbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Krystal Biotech, Inc.
Amryt Flies As Butterfly Skin Therapy Hits Late-Stage Goal
Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.
Finance Watch: Moderna Capitalizes On COVID-19 Vaccine Data Value Boost
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
Gene Therapy Companies Among Top M&A Targets In 2020
Zolgensma shows that a gene therapy can be a commercial hit – but there is still plenty to be wary of in this cutting-edge field.
Finance Watch: Gene Therapy, Targeted Oncology Driving IPOs Despite Biopharma Stock Shakiness
Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Topical Delivery
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule